Board of Directors

Daniel Spasic

Executive Advisor, Ampersand Capital

Daniel joined Ampersand as an Executive Advisor in 2023 and has more than 25 years in senior life science executive roles. He joined the clinical drug development team at Pharmacia & Upjohn in 1996. He later founded TFS (TFS Health Sciences), a global midsized clinical Contract Research Organization serving 250 biopharma customers worldwide. Daniel is the recipient of numerous entrepreneurial achievement awards.

In 2010, Daniel received the Swedish National Award as “Man of The Year” by Ernst & Young and in the same year was awarded the title “Entrepreneur of The Year” by Founders Alliance and Grant Thornton. His expertise covers biopharma outsourced services (drug discovery, pre- clinical and clinical) and research technology-enabled services. He is currently serving on the following Board of Directors: Ampersand portfolio company iuvo Bioscience (US), Avance Clinical (Australia), Trialbee (US), PathoQuest (France/US), Scantox (Denmark) and Inhalation Sciences (Sweden). Daniel holds a technical degree in Chemical Engineering and an OPM from Harvard Business School.

Eric B. Lev

General Partner, Ampersand Capital

Eric, who joined Ampersand in 2013, has 18 years of middle market healthcare investment experience. Eric’s current and past board seats include Alliance Pharma, Leinco Technologies, ALPCO, vivitide, CutisPharma, Genoptix, Interpace Diagnostics, LakePharma, Nexelis and Nexcelom Biosciences. Prior to Ampersand, he spent seven years as a member of the investment team at Water Street Healthcare Partners. Prior to Water Street, Eric worked at Beckman Coulter and at One Equity Partners. Eric holds a B.A. in Economics from Northwestern University and a M.B.A. from the University of Chicago.

Mario Reto

Vice President, Ampersand Capital Partners

Mario joined Ampersand in 2018. Most recently, he was an Associate at PNC Riverarch Capital, a middle market private equity firm. Prior to PNC Riverarch, Mario was at TM Capital, a middle market investment bank, where he focused on healthcare M&A transactions. Mario’s current and past board seats include AcuraBio and Precision Coating. Mario holds a B.S. in finance with a concentration in economics from Rochester Institute of Technology.

Ben Burton

President and CEO, iuvo BioScience

Prior to co-founding iuvo BioScience and taking on the roles of President and CEO, Ben was Vice President of Quality for the Pharmaceutical, Solutions and External Manufacturing organizations of Valeant Pharmaceuticals. Prior to the acquisition of Bausch + Lomb by Valeant, Ben served as Global VP of Quality for the Pharmaceutical Business Unit, and was a member of the B+L Global Leadership Team.

Earlier in his career, he held the position of Director, Quality and Technical Services for Norwich Pharmaceuticals (a contract manufacturing and development organization), responsible for driving new business development and revenue and leading the technical services organization (project managers, engineers, formulators, method developers, etc.) in delivering customer projects, as well as heading up the site quality organization. Ben began his career with Procter & Gamble Pharmaceuticals as a Process Engineer, moving up to roles of increasing responsibility in Product Development, OTC Engineering (Cayey, PR) and Global Clinical Supplies.

Ben holds a BS from Carnegie Mellon University with a double major in Chemical Engineering and Biomedical Engineering, and a dual MS/MAT in Chemistry and Education from Binghamton University.